JP5862669B2 - ロイコトリエン産生のオキサジアゾール阻害剤 - Google Patents

ロイコトリエン産生のオキサジアゾール阻害剤 Download PDF

Info

Publication number
JP5862669B2
JP5862669B2 JP2013526084A JP2013526084A JP5862669B2 JP 5862669 B2 JP5862669 B2 JP 5862669B2 JP 2013526084 A JP2013526084 A JP 2013526084A JP 2013526084 A JP2013526084 A JP 2013526084A JP 5862669 B2 JP5862669 B2 JP 5862669B2
Authority
JP
Japan
Prior art keywords
alkyl
mmol
independently
phenyl
cyclobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013526084A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013536235A5 (enExample
JP2013536235A (ja
Inventor
アレッサンドラ バルトロッツィ
アレッサンドラ バルトロッツィ
トッド ボサナック
トッド ボサナック
ジードン チェン
ジードン チェン
ロンベール ステファーヌ ドゥ
ロンベール ステファーヌ ドゥ
ジョナソン アラン ダインズ
ジョナソン アラン ダインズ
ジョン ディー フーバー
ジョン ディー フーバー
リウ　ウェイミン
ウェイミン リウ
ホー イン ロー
ホー イン ロー
プイ レン ローク
プイ レン ローク
モーウィック　ティナ　マリー
ティナ マリー モーウィック
ピーター アレン ネモト
ピーター アレン ネモト
アラン オラグ
アラン オラグ
ドリス リーター
ドリス リーター
ヘザー タイ
ヘザー タイ
リーフェン ウー
リーフェン ウー
レニー エム ジンデル
レニー エム ジンデル
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2013536235A publication Critical patent/JP2013536235A/ja
Publication of JP2013536235A5 publication Critical patent/JP2013536235A5/ja
Application granted granted Critical
Publication of JP5862669B2 publication Critical patent/JP5862669B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013526084A 2010-08-26 2011-08-23 ロイコトリエン産生のオキサジアゾール阻害剤 Active JP5862669B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37718110P 2010-08-26 2010-08-26
US61/377,181 2010-08-26
US201161511247P 2011-07-25 2011-07-25
US61/511,247 2011-07-25
PCT/US2011/048743 WO2012027322A1 (en) 2010-08-26 2011-08-23 Oxadiazole inhibitors of leukotriene production

Publications (3)

Publication Number Publication Date
JP2013536235A JP2013536235A (ja) 2013-09-19
JP2013536235A5 JP2013536235A5 (enExample) 2014-10-09
JP5862669B2 true JP5862669B2 (ja) 2016-02-16

Family

ID=44533215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013526084A Active JP5862669B2 (ja) 2010-08-26 2011-08-23 ロイコトリエン産生のオキサジアゾール阻害剤

Country Status (4)

Country Link
US (1) US8580829B2 (enExample)
EP (1) EP2609092B1 (enExample)
JP (1) JP5862669B2 (enExample)
WO (1) WO2012027322A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013500301A1 (en) 2010-08-16 2013-03-25 Boehringer Ingelheim Int Oxadiazole inhibitors of leukotriene production
WO2012027322A1 (en) 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
EP2619196B1 (en) * 2010-09-23 2015-09-16 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production
EA201300389A1 (ru) * 2010-09-23 2013-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Оксадиазольные ингибиторы продуцирования лейкотриена
WO2013116182A1 (en) * 2012-01-31 2013-08-08 Boehringer Ingelheim International Gmbh Heterocyclic compounds as inhibitors of leukotriene production
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
IN2015DN00099A (enExample) 2012-07-18 2015-05-29 Univ Saint Louis
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
EP3495359A1 (en) * 2013-02-04 2019-06-12 Janssen Pharmaceutica NV Flap modulators
KR101823488B1 (ko) 2013-10-14 2018-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 선택적으로 치환된 퀴놀린 화합물
ES2670550T3 (es) 2013-10-14 2018-05-30 Eisai R&D Management Co., Ltd. Derivados de quinolina selectivamente sustituidos
JP6244036B2 (ja) * 2014-01-21 2017-12-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 呼吸器合胞体ウイルス感染症の処置および予防のためのイミダゾール
TN2016000542A1 (en) 2014-06-03 2018-04-04 Idorsia Pharmaceuticals Ltd Pyrazole compounds and their use as t-type calcium channel blockers
HK1244806A1 (zh) 2015-12-30 2018-08-17 Saint Louis University 作為過氧乙醯硝酸整聯蛋白拮抗劑的間氮雜環氨基苯甲酸衍生物
HRP20220463T1 (hr) 2016-12-16 2022-05-27 Idorsia Pharmaceuticals Ltd Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa
WO2018141961A1 (en) 2017-02-06 2018-08-09 Idorsia Pharmaceuticals Ltd A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
US11208407B2 (en) 2017-08-02 2021-12-28 Merck Sharp & Dohme Corp. Substituted phenyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
EP3661910B1 (en) * 2017-08-02 2023-08-16 Merck Sharp & Dohme LLC Novel substituted pyridine compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
JP7805983B2 (ja) 2022-03-22 2026-01-26 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2260031T3 (es) 1999-08-06 2006-11-01 Janssen Pharmaceutica N.V. Derivados de 6-azauracilo que inhiben la interleucina-5.
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
AU2005295646B2 (en) 2004-10-18 2008-11-20 Merck Sharp & Dohme Corp. Diphenyl substituted alkanes as flap inhibitors
US7977359B2 (en) * 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
AU2007238878A1 (en) 2006-04-11 2007-10-25 Merck Sharp & Dohme Corp. Diaryl substituted alkanes
CA2787343C (en) 2006-06-26 2016-08-02 Amgen Inc. Compositions comprising modified lcat and uses thereof
ATE543810T1 (de) 2006-09-01 2012-02-15 Merck Sharp & Dohme Hemmer des 5-lipoxygenase aktivierenden proteins (flap)
AU2008241313A1 (en) 2007-04-20 2008-10-30 Merck Frosst Canada Ltd. Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CA2707360A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Diphenyl substituted alkanes
WO2009048547A1 (en) 2007-10-10 2009-04-16 Merck & Co., Inc. Diphenyl substituted cycloalkanes
CA2741666C (en) * 2008-10-31 2017-04-11 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
CA2749893A1 (en) 2009-02-04 2010-08-12 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
EP2568809A4 (en) 2010-05-12 2013-11-06 Univ Vanderbilt HETEROCYCLIC ALLOSTERE SULFON MGLUR4 POTENTIATORS, COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS
PH12013500301A1 (en) * 2010-08-16 2013-03-25 Boehringer Ingelheim Int Oxadiazole inhibitors of leukotriene production
WO2012027322A1 (en) 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
EA201300389A1 (ru) * 2010-09-23 2013-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Оксадиазольные ингибиторы продуцирования лейкотриена
EP2619196B1 (en) * 2010-09-23 2015-09-16 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production

Also Published As

Publication number Publication date
EP2609092B1 (en) 2015-04-01
US8580829B2 (en) 2013-11-12
EP2609092A1 (en) 2013-07-03
WO2012027322A1 (en) 2012-03-01
JP2013536235A (ja) 2013-09-19
US20120214787A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
JP2013536235A (ja) ロイコトリエン産生のオキサジアゾール阻害剤
EP2509975B1 (en) Benzimidazole inhibitors of leukotriene production
EP2606045B1 (en) Oxadiazole inhibitors of leukotriene production
CA2919783C (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
US9174980B2 (en) Heterocyclic compounds as inhibitors of leukotriene production
JP5828188B2 (ja) ロイコトリエン産生のオキサジアゾール阻害剤
JP5713511B2 (ja) ロイコトリエン産生のオキサジアゾール阻害剤
JP2019529413A (ja) Ｒｉｐｋ２の阻害剤としてのピリジンおよびピラジン化合物
US8829200B2 (en) Benzimidazole inhibitors of leukotriene production
JP5789888B2 (ja) ロイコトリエン生成のベンゾイミダゾールインヒビター
HK1183300A (en) Oxadiazole inhibitors of leukotriene production
HK1182389A (en) Oxadiazole inhibitors of leukotriene production
OA16344A (en) Oxadiazole inhibitors of leukotriene production.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140822

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140822

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150828

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151214

R150 Certificate of patent or registration of utility model

Ref document number: 5862669

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250